Edgewise Therapeutics Says Topline Data From 12-week Phase 2 Part D CIRRUS-HCM trial of EDG-7500 In Obstructive And Nonobstructive Hypertrophic Cardiomyopathy Show No Relationship Observed Between Multiple Measures Of Systolic Function And Concentration Of EDG-7500
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% –
– Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM –
– EDG-7500 administration continued to be generally well tolerated –
Login to comment